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Quantifying	the	future	clinical	burden	of	an	ageing	HIV-positive	
population	in	Italy:	a	mathematical	modelling	study
BACKGROUND
§ The	ageing	HIV-positive	population	has	been	
shown	to	experience	an	excess	burden	of	non-
communicable	diseases	(NCDs)	compared	to	
uninfected	persons1.	
§ Country-specific	forecasts	of	NCD	burden	will	be	
key	to	guide	future	HIV	policies	on	optimal	
management	of	multi-morbid	patients	and	
which	screening	and	treatment	services	will	be	
most	needed.	
§ Recent	model-based	projections	in	The	
Netherlands	showed	the	clinical	implications	of	
an	ageing	population	characterised	by	a	sharp	
increase	in	the	burden	of	NCDs,	potential	
complications	with	use	of	co-medication.2
AIM
§ To	use	model-based	analyses	to	provide	national	
forecast	of	the	future	age	structure	and	NCD	
burden	amongst	HIV-positive	patients	on	
antiretroviral	therapy	(ART)	in	the	United	States	
of	America	(USA).
METHOD	- DATA
§ The	model	was	developed	using	data	on	3,748	
commercially-insured	HIV-positive	patients	on	
ART	in	the	USA
§ Data	reflect	a	retrospective	analysis	of	
commercially-insured	HIV-positive	patients	in	
the	USA	drawn	from	a	geographically	
representative	national	sample	.	
§ National	surveillance	CDC	survey	data	was	used	
to	extrapolate	the	model	to	national	level3,4.	
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METHOD	- MODEL
§ We	adapted	an	individual-model	of	the	ageing	
HIV-positive	population	to	the	USA2.
§ Model	follows	ageing	HIV-positive	population	on	
ART	from	1st	January	2010	to	31st	December	
2035	or	death	and	probabilistically	simulates	
clinical	events	(hypertension,	dyslipidaemia,	
chronic	kidney	disease	(CKD),	diabetes,	non-
AIDS	defining	malignancies,	strokes	or	
myocardial	infractions	(MIs),	and	mortality).	
§ The	model	was	built	using	2005-2010	data,	and	
validated	against	2010-2015	out-of-sample	data	
to	ensure	projection	robustness	prior	to	
expanding	to	national	level.	
§ Model	results	were	based	on	the	average	of	100	
model	simulations.
§ The	model	projects	that	the	mean	age	amongst	
patients	on	ART	will	increase	from	48.9	to	57.8	
in	the	USA	between	2015	and	2035.
§ The	proportion	of	patients	on	ART	aged	≥	50	
years	old	will	increase	from	39%	to	74%	
between	2015	and	2035.			
Figure	1.	The	age	distribution	of	HIV-positive	
patients	on	antiretroviral	therapy	in	the	USA	
between	2015	and	2035.	
RESULTS	– FUTURE	BURDEN	OF	NCDS
§ The	proportion	of	patients	on	ART	with	no	NCDs	
will	decrease	from	29%	to	11%	between	2015	
and	2035	in	the	USA.		
§ The	proportion	of	patients	on	ART	with	three	or	
more	NCDs	will	increase	from	11%	to	44%	
between	2015	and	2035.	
Figure	2.	Stacked	bar	graph	of	projected	burden	
of	NCDs	in	HIV-positive	patients	on	antiretroviral	
therapy	between	2015	and	2035	in	the	USA.		
§ The	rising	NCD	burden	in	the	USA	will	be	driven	
by	CVD	(hypertension,	dyslipidaemia,	strokes	or	
MIs),	diabetes,	and	malignancy.	
§ CVD	will	contribute	the	greatest	burden,	
affecting	63%	of	patients	in	2015	and	85%	by	
2035.	
Figure	3.	Diagram	representing	the	changes	in	
relative	number	of	patients	with	specific	NCDs	
and	overlap	in	NCDs	in	A.	2015,	B.	2025,	and	C.	
2035.		The	area	represents	the	relative	number	of	
HIV-patients	with	NCDs.	Abbreviations:	
Cardiovascular	disease	(CVD).
§ HIV-positive	patients	in	the	USA	are	ageing	and	
will	suffer	from	an	increasing	NCD	burden.	
§ CVD,	malignancy	and	diabetes	in	particular	will	
contribute	to	NCD	burden.	
§ Trends	were	similar	to	forecasts	made	for	The	
Netherlands2.
§ Multi-morbidity	will	complicate	HIV	
management	due	to	potential	drug-interactions	
§ To	ensure	the	best	overall	long-term	health,	
optimal	selection	of	ART	and	co-medication	
choice	is	maintained	for	these	populations,	
multi-disciplinary	patient	management	and	
enhanced	communication	between	HIV	
specialists,	geriatric	medicine	and	primary	care	
must	be	developed.
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